冠心病合并慢性肾脏病晚期的治疗进展  

Progress in the treatment of coronary heart disease complicated with advanced chronic kidney disease

作　　者：孙铭亮 郭若玲 窦杰 杨慧惠 罗东雷 SUN Ming-liang;GUO Ruo-ling;DOU Jie;YANG Hui-hui;LUO Dong-lei(Graduate School of Chengde Medical University,Chengde 067000,China;Department of Cardiolgy,Chengde Central Hospital/Second Clinical College of Chengde Medical University,Chengde 067000,China)

机构地区：[1]承德医学院研究生院,河北省承德市067000 [2]承德市中心医院/承德医学院第二临床学院心血管内科

出　　处：《中国心血管病研究》2025年第1期69-73,共5页Chinese Journal of Cardiovascular Research

基　　金：承德市科学技术研究与发展计划(202109A019)。

摘　　要：冠心病(CHD)是危害人类健康的主要疾病之一,也是慢性肾脏病(CKD)患者死亡的主要原因,同时CKD也是CHD的独立危险因素。CHD合并CKD晚期患者高缺血风险与高出血风险并存,然而,针对CHD合并CKD晚期患者的治疗还没有明确标准,因为大多数CHD研究常把CKD晚期列入排除标准,致使对这一群体治疗策略的循证医学证据有限。本综述参考近期研究结果,对CHD合并CKD晚期患者治疗策略进行梳理,其中包括抗血小板药物治疗以及侵入性治疗手段的优缺点以及其可行性,为该群体的治疗策略提供参考。Coronary heart disease(CHD)is one of the main diseases endangering human health,which is the main cause of death in patients with chronic kidney disease(CKD),and CKD is also an independent risk factor for CHD.High ischemia risk and high risk of bleeding coexist in patients with CHD complicated with advanced CKD.However,there is a lack of clear clinical criteria for the treatment of patients with CHD and advanced CKD,because most of studies exclude patients with advanced CKD,resulting in limited evidence-based medical evidence.This review summarizes the recent teratment strategies for patients with CHD and advanced CKD,including the advantages and disadvantages of antiplatelet drug therapy and invasive treatments,as well as their feasibility,to provide reference for the treatment strategies for this population in clinical practice.

关 键 词：冠心病 慢性肾脏病 侵入性治疗 抗血小板治疗 

分 类 号：R541.4[医药卫生—心血管疾病]